Feedback

Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices

Affiliation
Perron Institute for Neurological and Translational Science ,Nedlands ,WA ,Australia
Roberts, Bradley;
Affiliation
Perron Institute for Neurological and Translational Science ,Nedlands ,WA ,Australia
Cooper, Zahra;
Affiliation
Perron Institute for Neurological and Translational Science ,Nedlands ,WA ,Australia
Landery, Georgia;
Affiliation
Division of Psychiatry ,School of Medicine ,The University of Western Australia ,Crawley ,WA ,Australia
Stanley, Susanne;
Affiliation
Curtin Medical School ,Curtin University ,Bentley ,WA ,Australia
Majda, Bernadette T.;
Affiliation
North Metropolitan Health Service ,Western Australian Department of Health ,Nedlands ,WA ,Australia
Collins, Khan R. L.;
Affiliation
Perron Institute for Neurological and Translational Science ,Nedlands ,WA ,Australia
Akkari, P. Anthony;
Affiliation
Perron Institute for Neurological and Translational Science ,Nedlands ,WA ,Australia
Hood, Sean D.;
Affiliation
Perron Institute for Neurological and Translational Science ,Nedlands ,WA ,Australia
Rodger, Jennifer

Introduction The field of pharmacogenetics (PGx) is experiencing significant growth, with increasing evidence to support its application in psychiatric care, suggesting its potential to personalize treatment plans, optimize medication efficacy, and reduce adverse drug reactions. However, the perceived utility and practicability of PGx for psychiatric treatment in youth remains underexplored. This study investigated perceived barriers and attitudes in Australian young adults towards the implementation of PGx testing to guide antidepressant treatment in primary care. Methods Semi-structured focus groups and interviews were conducted with 17 participants aged between 18 and 24 years. These sessions were recorded and transcribed before thematic analysis was used to identify collective themes. Results Three key themes were identified, including attitudes towards the medication prescription process, concerns and attitudes towards PGx testing, and perceived barriers to its clinical implementation. Although PGx testing was positively perceived by most participants, all participants shared concerns about PGx testing. Participants voiced concerns about the financial impact of PGx testing, the potential for treatment delays, and the accuracy of PGx testing in guiding antidepressant treatment. Additionally, participants noted that the low awareness and willingness of general practitioners to incorporate PGx testing into routine practice could hinder successful clinical implementation. Discussion Prior to the implementation of PGx testing into Australian primary practices, it is essential to acknowledge patient perspectives and ensure that clinical practices remain patient-focused. This study highlights important considerations for integrating PGx testing into antidepressant pharmacotherapy and emphasizes the need for future research to address and mitigate the perceived barriers of young adults.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Roberts, Cooper, Landery, Stanley, Majda, Collins, Akkari, Hood and Rodger.

Use and reproduction: